RIGID-MI: Impact of Peripheral Vascular Stiffness Assessment on Risk Prediction in Patients With Myocardial Infarction

Sponsor
University Hospital, Lille (Other)
Overall Status
Recruiting
CT.gov ID
NCT04058782
Collaborator
Fédération Française de Cardiologie (Other), Merck Sharp & Dohme LLC (Industry)
2,000
1
120.4
16.6

Study Details

Study Description

Brief Summary

Risk assessment after myocardial infarction is critical in daily practice and evolution toward heart failure especially diastolic heart failure remains a key issue. All consecutive patients with myocardial infarction (either STEMI or NSTEMI but excluding type 2 MI) presenting at university hospital of Lille within 48 hours after symptom onset will be recruited in the RIGID-MI registry. The RIGID-MI study proposes to deeply evaluate at 1 month after MI: peripheral vascular disease, vascular stiffness, ventriculo-arterial coupling and other usual risk factors. The main objective is to identify clinical, biological and imaging parameters associated with poor prognosis, especially evolution toward diastolic heart failure, recurrence of MI, and bleeding.

Condition or Disease Intervention/Treatment Phase
  • Other: Imaging evaluation for vascular assessment

Study Design

Study Type:
Observational
Anticipated Enrollment :
2000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Impact of Peripheral Vascular Stiffness Assessment on Risk Prediction in Patients With Myocardial Infarction
Actual Study Start Date :
Feb 17, 2020
Anticipated Primary Completion Date :
Mar 1, 2030
Anticipated Study Completion Date :
Mar 1, 2030

Arms and Interventions

Arm Intervention/Treatment
Patients with myocardial

Other: Imaging evaluation for vascular assessment
At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation

Outcome Measures

Primary Outcome Measures

  1. MACE: Major adverse cardiovascular events [at 5 years]

    A composite of cardiovascular death, ischemic stroke, myocardial infarction, systemic embolism, acute limb ischemia, coronary revascularization, hospitalization for heart failure

Secondary Outcome Measures

  1. Cardiovascular death [at 5 years]

  2. Myocardial infarction [at 5 years]

  3. Ischemic stroke [at 5 years]

  4. Systemic embolism [at 5 years]

  5. Acute limb ischemia [at 5 years]

  6. Coronary revascularization [at 5 years]

  7. Hospitalization for heart failure [at 5 years]

  8. All-cause death [at 5 years]

  9. Bleeding as assessed by Bleeding Academic Research Consortium (BARC) [at 5 years]

  10. Bleeding as assessed by GUSTO Bleeding Criteria [at 5 years]

    Global Utilization Of Streptokinase And Tpa For Occluded Arteries (GUSTO) definition for bleeding range to 1. Severe or Life-threatening/ 2. Moderate/ 3. Mild

  11. Bleeding as assessed by Thrombolysis in Myocardial Infarction (TIMI) criteria [at 5 years]

  12. Bleeding as assessed by ISTH definitions [at 5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Signed informed consent

  • Affiliated to national health insurance (French social security number)

  • Presenting with MI within 48 hours of symptom onset

Exclusion Criteria:
  • Patient under curatorship

  • Type 2 MI

  • Presenting with MI after 48 hours of symptom onset

  • Pregnancy or lactating

  • Refuse to participate

  • No national health insurance (No French social security number)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institut Coeur-Poumon, CHU Lille France 59037

Sponsors and Collaborators

  • University Hospital, Lille
  • Fédération Française de Cardiologie
  • Merck Sharp & Dohme LLC

Investigators

  • Principal Investigator: Gilles Lemesle, MD, University Hospital, Lille

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Lille
ClinicalTrials.gov Identifier:
NCT04058782
Other Study ID Numbers:
  • 2018_43
  • 2018-A03276-49
First Posted:
Aug 16, 2019
Last Update Posted:
Mar 2, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Lille
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 2, 2022